These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 1746507)

  • 41. Single high-dose buprenorphine for opioid craving during withdrawal.
    Ahmadi J; Jahromi MS; Ghahremani D; London ED
    Trials; 2018 Dec; 19(1):675. PubMed ID: 30526648
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Double successful buprenorphine/naloxone induction to facilitate cardiac transplantation in an iatrogenically opiate-dependent patient.
    Rodgman C; Pletsch G
    J Addict Med; 2012 Jun; 6(2):177-8. PubMed ID: 22456493
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A case of acute psychosis after buprenorphine withdrawal: abrupt versus progressive discontinuation could make a difference.
    Weibel S; Mallaret M; Bennouna-Greene M; Bertschy G
    J Clin Psychiatry; 2012 Jun; 73(6):e756. PubMed ID: 22795215
    [No Abstract]   [Full Text] [Related]  

  • 44. Characterizing opioid withdrawal during double-blind buprenorphine detoxification.
    Dunn KE; Saulsgiver KA; Miller ME; Nuzzo PA; Sigmon SC
    Drug Alcohol Depend; 2015 Jun; 151():47-55. PubMed ID: 25823907
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Late antinociception and lower untoward effects of concomitant intrathecal morphine and intravenous buprenorphine in humans.
    Beltrutti D; Niv D; Ben-Abraham R; Di Santo S; Weinbroum AA
    J Clin Anesth; 2002 Sep; 14(6):441-6. PubMed ID: 12393113
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans.
    Eissenberg T; Greenwald MK; Johnson RE; Liebson IA; Bigelow GE; Stitzer ML
    J Pharmacol Exp Ther; 1996 Feb; 276(2):449-59. PubMed ID: 8632309
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain.
    Davis MP
    J Support Oncol; 2012; 10(6):209-19. PubMed ID: 22809652
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A controlled comparison of buprenorphine and clonidine for acute detoxification from opioids.
    Cheskin LJ; Fudala PJ; Johnson RE
    Drug Alcohol Depend; 1994 Oct; 36(2):115-21. PubMed ID: 7851278
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A double-blind comparison of the relative efficacy, side effects and cost of buprenorphine and morphine in patients after cardiac surgery.
    Rabinov M; Rosenfeldt FL; McLean AJ
    Aust N Z J Surg; 1987 Apr; 57(4):227-31. PubMed ID: 3307727
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Naloxone rapidly evokes endogenous kappa opioid receptor-mediated hyperalgesia in naïve mice pretreated briefly with GM1 ganglioside or in chronic morphine-dependent mice.
    Crain SM; Shen KF
    Brain Res; 2007 Sep; 1167():31-41. PubMed ID: 17692296
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Effectiveness and tolerance of tramadol in cancer pain. A comparative study with respect to buprenorphine].
    Bono AV; Cuffari S
    Drugs; 1997; 53 Suppl 2():40-9. PubMed ID: 9190324
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Withdrawal syndrome in 2 drug addicts after intravenous injection of buprenorphine?].
    Gourarier L; Lowenstein W; Gisselbrecht M; Chauveau JM; Haas C; Durand H
    Presse Med; 1996 Sep; 25(27):1239-40. PubMed ID: 8949735
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Naloxone-induced withdrawal in patients with buprenorphine dependence.
    Nigam AK; Srivastava RP; Saxena S; Chavan BS; Sundaram KR
    Addiction; 1994 Mar; 89(3):317-20. PubMed ID: 8173501
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A randomized, double-blind, placebo-controlled, cross-over pilot study to assess the effects of long-term opioid drug consumption and subsequent abstinence in chronic noncancer pain patients receiving controlled-release morphine.
    Cowan DT; Wilson-Barnett J; Griffiths P; Vaughan DJ; Gondhia A; Allan LG
    Pain Med; 2005; 6(2):113-21. PubMed ID: 15773875
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [The transdermal 7-day buprenorphine patch--an effective and safe treatment option, if tramadol or tilidate/naloxone is insufficient. Results of a non-interventional study].
    Schutter U; Ritzdorf I; Heckes B
    MMW Fortschr Med; 2010 Jul; 152 Suppl 2():62-9. PubMed ID: 21591321
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Buprenorphine and morphine efficacy in postoperative pain: a double-blind multiple-dose study.
    Ouellette RD
    J Clin Pharmacol; 1982 Apr; 22(4):165-72. PubMed ID: 7047580
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Buprenorphine versus morphine for patient-controlled analgesia after cholecystectomy.
    Dingus DJ; Sherman JC; Rogers DA; DiPiro JT; May R; Bowden TA
    Surg Gynecol Obstet; 1993 Jul; 177(1):1-6. PubMed ID: 8322143
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Buprenorphine vs. morphine via the epidural route: a controlled comparative clinical study of respiratory effects and analgesic activity.
    Pasqualucci V; Tantucci C; Paoletti F; Dottorini ML; Bifarini G; Belfior R; Berioli MB; Grassi V; Sorbini CA
    Pain; 1987 Jun; 29(3):273-286. PubMed ID: 3614964
    [TBL] [Abstract][Full Text] [Related]  

  • 59. STUDYING THE PHYSICAL DEPENDENCE ON AND TOLERANCE TO THE ANTINOCICEPTIVE EFFECT OF RU-1205 SUBSTANCE.
    Grechko OY; Shtareva DM; Spasov AA; Litvinov LA; Rashchenko AI
    Eksp Klin Farmakol; 2016 Aug; 79(4):8-11. PubMed ID: 29949697
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Acute opioid physical dependence in humans: effect of varying the morphine-naloxone interval. I.
    Heishman SJ; Stitzer ML; Bigelow GE; Liebson IA
    J Pharmacol Exp Ther; 1989 Aug; 250(2):485-91. PubMed ID: 2760839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.